Analyst consensus rating
Maze Therapeutics Analyst Rating: Strong Buy
Direct answer
Maze Therapeutics's consensus rating is Strong Buy.
12 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $61.50.
Forecast evidence checked October 11, 2026.
Get free Maze Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $27.11
- Average price target
- $61.50
- High price target
- $110.00
- Low price target
- $46.00
- Low target gap
- +69.7%
- Target upside
- +126.9%
- High target gap
- +305.8%
- Target range width
- 236.1%
- Consensus rating
- Strong Buy
- Analysts
- 12
- Evidence date
- October 11, 2026
- Valid through
- October 18, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Maze Therapeutics?
Maze Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $61.50.
How far are Maze Therapeutics's low and high targets from the recorded price?
The low target implies +69.7%, while the high target implies +305.8%.
How many analysts are included in Maze Therapeutics's consensus?
The verified consensus includes 12 analysts.
How is Maze Therapeutics's target upside or downside calculated?
The average target of $61.50 is divided by the recorded price of $27.11, then one is subtracted to produce +126.9%. This does not guarantee a future return.
When was Maze Therapeutics's analyst forecast verified?
The data was verified on 2026-10-11. The dataset is valid through 2026-10-18.